Skip to main content
Log in

Chemical Degradation Kinetics of Recombinant Hirudin (HVI) in Aqueous Solution: Effect of pH

  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Abstract

Purpose. To gain information on the chemical stability pattern and the kinetics of the degradation of recombinant hirudin variant HVI (rHir), a thrombin-specific inhibitor protein of 65 amino acids, in aqueous solution as a function of pH.

Methods. Stability of rHir was monitored at 50°C in the framework of a classical pH-stability study in aqueous buffers pH 1−9.5. Two capillary electrophoresis (CE) protocols were used; one for the kinetics of succinimide formation at Asp53-Gly54 (C-terminal tail) and Asp33-Gly34 (loop section), the other for the kinetics of rHir degradation. To check for potential effects of conformational changes by thermal denaturation, circular dichroism (CD) measurements were performed between 25 and 80°C.

Results. Throughout the pH range studied no effect of thermal denaturation on rHir confirmation at 50°C was observed. rHir was most stable at a neutral pH whereas, at slightly acidic pH, an intermediate stability plateau was found. Both, strongly acidic and alkaline conditions led to fast rHir degradation. Depending on the pH of degradation, rHir was found to degrade in various combinations of multiple parallel and sequential degradation patterns. Special focus was on succinimide formation at Asp53-Gly54 (C-terminal tail) and Asp33-Gly34 (loop) and on the potential of isoAsp formation in position 53 and 33.

Conclusions. Chemical rHir stability in the intermediate pH range depends strongly on succinimide formation. At slightly acidic conditions succinimides represent the major degradation product (up to 40%). Around neutral pH succinimides react further, presumably by isoAsp formation, and concentrations remain low. Relative preference of succinimide formation in the C-terminal tail domain versus the loop domain is explained by higher backbone flexibility in the tail.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. F. Markwardt. Untersuchungen über Hirudin. Naturwissenschaften 42:537–538 (1955).

    Google Scholar 

  2. W. E. Märki, H. Grossenbacher, M. G. Grütter, M. H. Liersch, B. Meyhack, and J. Heim. Recombinant hirudin: genetic engineering and structure analysis. Semin. Thromb. Hemostasis 17:88–93 (1991).

    Google Scholar 

  3. J.-Y. Chang. Stability of hirudin, a thrombin-specific inhibitor. J. Biol. Chem. 266(17):10839–43 (1991).

    PubMed  Google Scholar 

  4. H. Grossenbacher, W. Märki, M. Coulot, D. Müller, and W. J. Richter. Characterization of succinimide-type dehydration products of recombinant hirudin variant 1 by electrospray tandem mass spectrometry. Rapid Communications in Mass Spectrometry 7:1082–1085 (1993).

    PubMed  Google Scholar 

  5. S. Capasso, L. Mazzarella, F. Sica, A. Zagari, and S. Salvadori. Spontaneous cyclization of the aspartic acid side chain to the succinimide derivative. J. Chem. Soc. Chem. Commun. 919–921 (1992).

  6. T. Geiger and St. Clarke. Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides. J. Biol. Chem. 262(2):785–794 (1987).

    PubMed  Google Scholar 

  7. St. J. Wearne and T. E. Creighton. Effect of protein conformation on rate of deamidation: Ribonuclease A. Proteins 5:8–12 (1989).

    PubMed  Google Scholar 

  8. M. Xie, D. V. Velde, M. Morton, R. T. Borchardt, and R. L. Schowen. pH-induced change in the rate-determining step for the hydrolysis of the Asp/Asn-derived cyclic-imide intermediate in protein degradation. J. Am. Chem. Soc. 118:8955–8956 (1996).

    Google Scholar 

  9. P. Schindler, D. Müller, W. Märki, H. Grossenbacher, and W. J. Richter. Characterization of a β-Asp33 isoform of recombinant hirudin sequence Variant 1 by low-energy collision-induced dissociation. J. Mass Spectrom. 24:967–974 (1996).

    Google Scholar 

  10. A. Tuong, M. Maftouh, C. Ponthus, O. Whitechurch, C. Roitsch, and C. Picard. Characterization of the deamidated forms of recombinant hirudin. Biochemistry 31:8291–8299 (1992).

    PubMed  Google Scholar 

  11. A. P. Nordmann. Spectroscopic and related studies of recombinant hirudin, human neuropeptide Y and analogues, Ph.D. Thesis, Birkbeck College, London, 1996, p. 41.

    Google Scholar 

  12. S. J. Advant. The effect of solution environment on the stability and aggregation of recombinant human interleukin-2. Ph.D. Thesis, University of Connecticut, U.M.I. Publ., Ann Arbor (MI), USA, 1994, pp. 31–34.

    Google Scholar 

  13. F. Markwardt. The development of hirudin as an antithrombotic drug. Thromb. Res. 74(1):1–23 (1994).

    PubMed  Google Scholar 

  14. H. Haruyama and K. Wüthrich. Conformation of recombinant desulfatohirudin in aqueous solution determined by nuclear magnetic resonance. Biochemistry 28:4301–4312 (1989).

    PubMed  Google Scholar 

  15. K. Forrer, P. Girardot, M. Dettwiler, W. Märki, H. Grossenbacher, and E. Gassmann. Different modes of capillary electrophoresis for the analysis of recombinant hirudin. 9th International Symposium on Capillary Electrophoresis. Budapest, Hungary. 1994.

  16. C. Dette and H. Wätzig. Separation of r-hirudin from similar substances by capillary electrophoresis. J. Chromatogr. A 700:89–94 (1995).

    PubMed  Google Scholar 

  17. U. Gietz. Therapeutic protein formulation for sustained delivery: Formulation aspects and stability. Ph.D. Thesis, Department of Pharmacy ETH, Zürich, 1997.

    Google Scholar 

  18. S. Clarke. Propensity for spontaneous succinimide formation from aspartyl and asparaginyl residues in cellular proteins. Int. J. Peptide Protein Res. 30:808–821 (1987).

    Google Scholar 

  19. A. A. Kossiakoff. Tertiary structure is a principal determinant to protein deamidation. Science 240:191–194 (1988).

    PubMed  Google Scholar 

  20. C. Oliyai and R. T. Borchardt. Chemical pathways of peptide degradation. IV. Pathways, kinetics and mechanism of degradation of an aspartyl residue in a model hexapeptide. Pharm. Res. 10:95–102 (1993).

    PubMed  Google Scholar 

  21. T. V. Brennan and St. Clarke. Spontaneous degradation of poly-peptides at aspartyl and asparaginyl residues: Effect of the solvent dielectric. Protein Sci. 2:331–338 (1993).

    PubMed  Google Scholar 

  22. T. J. Ahern and A. M. Klibanov. The mechanism of irreversible enzyme inactivation at 100°C. Science 228:1280–1284 (1985).

    PubMed  Google Scholar 

  23. R. Pearlman and T. A. Bewley. Stability and characterization of human growth hormone. In: Y. J. Wang and R. Pearlman (eds.), Stability and characterization of protein and peptide drugs, Plenum Press, New York, 1993, pp 1.

    Google Scholar 

  24. R. I. Senderoff, S. C. Wootton, A. M. Boctor, T. M. Chen, A. B. Giordani, T. N. Julian, and G. W. Radebaugh. Aqueous stability of human epidermal growth factor 1–48. Pharm. Res. 11(12):1712–1720 (1994).

    PubMed  Google Scholar 

  25. A. Otto and R. Seckler. Characterization, stability and refolding of recombinant hirudin. Eur. J. Biochem. 202:67–73 (1991).

    PubMed  Google Scholar 

  26. R. Khurana, A. T. Hate, U. Nath, and J. B. Udgaonkar. pH dependence of the stability of barstar to chemical and thermal denaturation. Protein Science 4:1133–1144 (1995).

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gietz, U., Alder, R., Langguth, P. et al. Chemical Degradation Kinetics of Recombinant Hirudin (HVI) in Aqueous Solution: Effect of pH. Pharm Res 15, 1456–1462 (1998). https://doi.org/10.1023/A:1011918108849

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1011918108849

Navigation